Myant enters US market with mmHg's platform for remote blood pressure and cardiovascular care
Myant Corp. has announced its acquisition of mmHg Inc., a digital health company specializing in remote blood pressure monitoring, cardiovascular risk reduction, and chronic disease management.
According to its press release, this move expands Myant’s geographic reach into the US, where mmHg has an established customer base.
The acquisition also strengthens Myant's partnership with A&D Medical, a major manufacturer of accurate medical devices and health products.
The acquisition forms part of Myant’s strategy to advance personalized, AI-enabled remote healthcare under the vision of ‘prevention through precision.’
mmHg's platform focuses on delivering efficient, guideline-aligned care for cardiovascular health, particularly in remote settings. The software enables healthcare providers to remotely monitor blood pressure and other vital cardiovascular indicators.
By integrating patient data with clinical best practices, mmHg enhances decision-making and facilitates timely interventions.
Its platform is used by institutions such as Beth Israel Deaconess (Harvard Medical), Johns Hopkins, Columbia University, NYU, Tulane University, and the University of British Columbia to improve patient outcomes and support clinical research.
Combining mmHg’s remote monitoring solutions with Myant’s material and textile computing technology will provide continuous, real-time patient data for healthcare providers.
This integration aims to detect health risks earlier, deliver personalized treatment plans, and improve chronic condition management. These advancements are expected to reduce hospital visits, improve health outcomes, and enhance quality of life.
Tony Chahine, CEO of Myant, emphasized that the company is committed to “make healthy aging a reality for millions.”
He noted that the acquisition strengthens Myant’s ability to provide cardiovascular monitoring and risk management solutions, aiming to transform digital health and address chronic conditions.
Peter Wood, co-founder and Chief Operating Officer at mmHg, highlighted the collaboration's potential, stating, “The combination of Myant’s cutting-edge textile technology and mmHg’s clinically-infused software architecture will no doubt create the next generation of personalized care delivery.”
He explained that this innovation allows patients to transmit clinical-grade, continuous vitals data to a platform designed for efficient and clinical data presentation.
The press release said this acquisition aligns with Myant's efforts to use AI and advanced materials to improve patient outcomes and expand its vertically integrated solutions for healthcare.
